CLEVELAND--(BUSINESS WIRE)--Arteriocyte, Inc., a leading clinical stage biotechnology company developing cellular therapies for ischemic diseases, announced today the successful award of a $310,000 National Institute of Health grant to evaluate its cellular therapy product (ACY001) as a potential treatment for diabetic retinopathies in collaboration with researchers at Cleveland Clinic. The award was made by the NIH Eye Institute as a part of the Small Business Technology Transfer (STTR) program.
